Separate and combined effects of the GABA reuptake inhibitor tiagabine and Δ 9-THC in humans discriminating Δ 9-THC

Drug and Alcohol Dependence

Volumn 122, Issue 1-2, 2012, Pages 61-69

  Lile, Joshua A ^a   Kelly, Thomas H ^a,b   Hays, Lon R ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Cardiovascular; Digit symbol substitution task; Drug discrimination; Marijuana; Repeated acquisition task; Subjective effects

Indexed keywords

4 AMINOBUTYRIC ACID; CANNABIS; DRONABINOL; PLACEBO; TIAGABINE;

ADULT; ARTICLE; CANNABIS ADDICTION; CONTROLLED STUDY; DISCRIMINATIVE STIMULUS; DOSE RESPONSE; DRUG DISCRIMINATION; DRUG EFFECT; FEMALE; HEART RATE; HUMAN; HUMAN EXPERIMENT; MALE; PERCEPTIVE DISCRIMINATION; PRIORITY JOURNAL; PSYCHOMOTOR PERFORMANCE; SELF REPORT; TASK PERFORMANCE;

ADOLESCENT; ADULT; DISCRIMINATION (PSYCHOLOGY); FEMALE; GABA UPTAKE INHIBITORS; HEART RATE; HUMANS; MALE; NIPECOTIC ACIDS; PSYCHOMOTOR PERFORMANCE; QUESTIONNAIRES; TETRAHYDROCANNABINOL;

CANNABIS; CANNABIS SATIVA;

EID: 84858441801     PISSN: 03768716     EISSN: 18790046     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2011.09.010     Document Type: Article

References (82)

1. Antonelli T., Tomasini M.C., Mazza R., Fuxe K., Gaetani S., Cuomo V., Tanganelli S., Ferraro L. Cannabinoid CB1 and cholecystokinin CCK2 receptors modulate, in an opposing way, electrically evoked [3H]GABA efflux from rat cerebral cortex cell cultures: possible relevance for cortical GABA transmission and anxiety. J. Pharmacol. Exp. Ther. 2009, 329:708-717.
2. Banerjee S.P., Snyder S.H., Mechoulam R. Cannabinoids: influence on neurotransmitter uptake in rat brain synaptosomes. J. Pharmacol. Exp. Ther. 1975, 94:74-81.
3. Bestard J.A., Toth C.C. An open-label comparison of nabilone and gabapentin as adjuvant therapy or monotherapy in the management of neuropathic pain in patients with peripheral neuropathy. Pain Pract. 2011, 11:353-368.
4. Bialer M. Comparative pharmacokinetics of the newer antiepileptic drugs. Clin. Pharmacokinet. 1993, 24:441-452.
5. Breivogel C.S., Childers S.R. The functional neuroanatomy of brain cannabinoid receptors. Neurobiol. Dis. 1998, 5:417-431.
6. Breivogel C.S., Griffin G., Di Marzo V., Martin B.R. Evidence for a new G protein-coupled cannabinoid receptor in mouse brain. Mol. Pharmacol. 2001, 60:155-163.
7. Brunbech L., Sabers A. Effect of antiepileptic drugs on cognitive function in individuals with epilepsy: a comparative review of newer versus older agents. Drugs 2002, 62:593-604.
8. Castellano C., Rossi-Arnaud C., Cestari V., Costanzi M. Cannabinoids and memory: animal studies. CNS Neurol. Disord. Drug Targets 2003, 2:389-402.
9. Compton D.R., Rice K.C., DeCosta B.R., Razdan R.K., Melvin L.S., Johnson M.R., Martin B.R. Cannabinoid structure-activity relationships: correlation of receptor binding and in vivo activities. J. Pharmacol. Exp. Ther. 1993, 265:218-226.
10. 9-THC-induced responses and apparent agonist activity. J. Pharmacol. Exp. Ther. 1996, 277:586-594.
11. A receptor-mediated responses in a grease-gap recording preparation of the rat hippocampal slice. Neuropharmacology 1997, 36:1387-1392.
12. Engler B., Freiman I., Urbanski M., Szabo B. Effects of exogenous and endogenous cannabinoids on GABAergic neurotransmission between the caudate-putament and the globus pallidus in the mouse. J. Pharmacol. Exp. Ther. 2006, 316:608-617.
13. Freund T.F. Interneuron diversity series: rhythm and mood in perisomatic inhibition. Trends Neurosci. 2003, 26:489-495.
14. Fritz N., Glogau S., Hoffmann J., Rademacher M., Elger C.E., Helmstaedter C. Efficacy and cognitive side effects of tiagabine and topiramate in patients with epilepsy. Epilepsy Behav. 2005, 6:373-381.
15. Frosini M., Valoti M., Sgaragli G. Changes in rectal temperature and ECoG spectral power of sensorimotor cortex elicited in conscious rabbits by i.c.v. injection of GABA, GABA(A) and GABA(B) agonists and antagonists. Br. J. Pharmacol. 2004, 141:152-162.
16. Gabitril Product Information, 2009. Cephalon, Inc., Frazer, PA.
17. Glass R.M., Uhlenhuth E.H., Hartel F.W., Schuster C.R., Fischman M.W. A single dose study of nabilone, a synthetic cannabinoid. Psychopharmacology (Berl) 1980, 71:137-142.
18. Griffiths R.R., Troisi J.R., Silverman K., Mumford G.K. Multiple-choice procedure: an efficient approach for investigating drug reinforcement in humans. Behav. Pharmacol. 1993, 4:3-13.
19. Hall W.D., Lynskey M. Is cannabis a gateway drug? Testing hypotheses about the relationship between cannabis use and the use of other illicit drugs. Drug Alcohol Rev. 2005, 24:39-48.
20. Haney M., Hart C.L., Vosburg S.K., Nasser J., Bennett A., Zubaran C., Foltin R.W. Marijuana withdrawal in humans: effects of oral THC or divalproex. Neuropsychopharmacology 2004, 29:158-170.
21. Hart C.L., Haney M., Vosburg S.K., Comer S.D., Foltin R.W. Reinforcing effects of oral Delta9-THC in male marijuana smokers in a laboratory choice procedure. Psychopharmacology (Berl) 2005, 181:237-243.
22. Hashimotodani Y., Ohno-Shosaku T., Kano M. Endocannabinoids and synaptic function in the CNS. Neuroscientist 2007, 13:127-137.
23. Heishman S.J., Stitzer M.L., Yingling J.E. Effects of tetrahydrocannabinol content on marijuana smoking behavior, subjective reports and performance. Pharmacol. Biochem. Behav. 1989, 34:173-179.
24. Hohmann A.G. Spinal and peripheral mechanisms of cannabinoid antinociception: behavioral, neurophysiological and neuroanatomical perspectives. Chem. Phys. Lipids 2002, 121:173-190.
25. Hohmann A.G., Herkenham M. Localization of cannabinoid CB(1) receptor mRNA in neuronal subpopulations of rat striatum: a double-label in situ hybridization study. Synapse 2000, 37:71-80.
26. Hollister L.E., Gillespie H.K., Ohlsson A., Lindgren J.E., Wahlen A., Agurell S. Do plasma concentrations of delta 9-tetrahydrocannabinol reflect the degree of intoxication?. J. Clin. Pharmacol. 1981, 21:171S-177S.
27. Holtzman S.G., Locke K.W. Neural mechanisms of drug stimuli: experimental approaches. Psychopharmacol. Ser. 1988, 4:138-153.
28. Huestis M.A., Boyd S.J., Heishman S.J., Preston K.L., Bonnet D., Le Fur G., Gorelick D.A. Single and multiple doses of rimonabant antagonize acute effects of smoked cannabis in male cannabis users. Psychopharmacology (Berl) 2007, 194:505-515.
29. 1-selective cannabinoid receptor antagonist SR141716. Arch. Gen. Psychiatry 2001, 58:322-328.
30. 9-THC or (R)-methanandamide. Psychopharmacology (Berl) 2006, 188:315-323.
31. Järbe T.U., Liu Q., Makriyannis A. Antagonism of discriminative stimulus effects of delta(9)-THC and (R)-methanandamide in rats. Psychopharmacology (Berl) 2006, 184:36-45.
32. Kamien J.B., Bickel W.K., Higgins S.T., Hughes J.R. The effects of delta 9-tetrahydrocannabinol on repeated acquisition and performance of response sequences and on self-reports in humans. Behav. Pharmacol. 1994, 5:71-78.
33. Karst M., Wippermann S., Ahrens J. Role of cannabinoids in the treatment of pain and (painful) spasticity. Drugs 2010, 70:2409-2438.
34. Kastberg H., Jansen J.A., Cole G., Wesnes K. Tiagabine: absence of kinetic or dynamic interactions with ethanol. Drug Metabol. Drug Interact. 1998, 14:259-273.
35. Kelly T.H., Foltin R.W., Emurian C.S., Fischman M.W. Performance-based testing for drugs of abuse: dose and time profiles of marijuana, amphetamine, alcohol and diazepam. J. Anal. Toxicol. 1993, 17:264-272.
36. Kelly T.H., Foltin R.W., Fischman M.W. Multidimensional behavioral effects of marijuana. Prog. Neuropsychopharmacol. Biol. Psychiatry 1990, 14:885-902.
37. Laughlin T.M., Tram K.V., Wilcox G.L., Birnbaum A.K. Comparison of antiepileptic drugs tiagabine, lamotrigine, and gabapentin in mouse models of acute, prolonged, and chronic nociception. J. Pharmacol. Exp. Ther. 2002, 302:1168-1175.
38. Levin F.R., McDowell D., Evans S.M., Nunes E., Akerele E., Donovan S., Vosburg S.K. Pharmacotherapy for marijuana dependence: a double-blind, placebo-controlled pilot study of divalproex sodium. Am. J. Addict. 2004, 13:21-32.
39. 9-THC. Clin. Neuropharmacol. 2010, 33:235-242.
40. 9-THC in humans discriminating Δ(9)-THC. Drug Alcohol Depend. 2011, 116:86-92.
41. 9-tetrahydrocannabinol. Psychopharmacology (Berl) 2009, 203:241-250.
42. Lile J.A., Stoops W.W., Glaser P.E., Hays L.R., Rush C.R. Acute administration of the GABA reuptake inhibitor tiagabine does not alter the effects of oral cocaine in humans. Drug Alcohol Depend. 2004, 76:81-91.
43. Mailleux P., Vanderhaeghen J.J. Distribution of neuronal cannabinoid receptor in the adult rat brain: a comparative receptor binding radioautography and in situ hybridization histochemistry. Neuroscience 1992, 48:6555-6568.
44. Maneuf Y.P., Nash J.E., Crossman A.R., Brotchie J.M. Activation of the cannabinoid receptor by delta 9-tetrahydrocannabinol reduces gamma-aminobutyric acid uptake in the globus pallidus. Eur. J. Pharmacol. 1996, 308:161-164.
45. Marinol® Product Information, 2006. Solvay Pharmaceuticals Inc., Marietta, GA.
46. Mason B.J. A Double-Blind, Placebo-Controlled Study of Gabapentin Treatment of Cannabis Dependence. Presentation at the 49th Annual New Research Approaches for Mental Health Interventions Meeting, " Translating Mental Health Research into Practice: Accelerating the Pace" 2009.
47. Matsuda L.A., Lolait S.J., Brownstein M.J., Young A.C., Bonner T.I. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990, 346:561-564.
48. McLeod D.R., Griffiths R.R., Bigelow G.E., Yingling J.E. An automated version of the Digit Symbol Substitution Test (DSST). Behav. Res. Methods Instrument. 1982, 14:463-466.
49. 9-THC. J. Pharmacol. Exp. Ther. 2006, 319:1211-1218.
50. Moreira F.A., Wotjak C.T. Cannabinoids and anxiety. Curr. Top. Behav. Neurosci. 2010, 2:429-450. Review.
51. Munro S., Thomas K.L., Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993, 365:61-65.
52. Nakano S., Gillespie H.K., Hollister L.E. A model for evaluation of antianxiety drugs with the use of experimentally induced stress: comparison of nabilone and diazepam. Clin. Pharmacol. Ther. 1978, 23:54-62.
53. Ohno-Shosaku T., Maejima T., Kano M. Endogenous cannabinoids mediate retrograde signals from depolarized postsynaptic neurons to presynaptic terminals. Neuron 2001, 29:729-738.
54. Onaivi E.S. Neuropsychobiological evidence for the functional presence and expression of cannabinoid CB2 receptors in the brain. Neuropsychobiology 2006, 54:231-246.
55. 2 receptors. Pharmacol. Ther. 1997, 74:129-180.
56. Pertwee R.G., Browne S.E., Ross T.M., Stretton C.D. An investigation of the involvement of GABA in certain pharmacological effects of delta-9-tetrahydrocannabinol. Pharmacol. Biochem. Behav. 1991, 40:581-585.
57. Pertwee R.G., Greentree S.G., Swift P.A. Drugs that stimulate or facilitate central GABAergic transmission interact synergistically with delta-9-tetrahydrocannabinol-induced to produce marked catalepsy in mice. Neuropharmacology 1988, 27:1265-1270.
58. Romero J., de Miguel R., Ramos J.A., Fernández-Ruiz J.J. The activation of cannabinoid receptors in striatonigral GABAergic neurons inhibited GABA uptake. Life Sci. 1998, 62:351-363.
59. Rosenberg G. The mechanisms of action of valproate in neuropsychiatric disorders: can we see the forest for the trees?. Cell. Mol. Life Sci. 2007, 64:2090-2103.
60. Rubino T., Parolaro D. Long lasting consequences of cannabis exposure to adolescence. Mol. Cell. Endocrinol. 2008, 286:S108-S113.
61. Rush C.R., Kollins S.H., Pazzaglia P.J. Discriminative-stimulus and participant-rated effects of methylphenidate, bupropion and triazolam in d-amphetamine trained humans. Exp. Clin. Psychopharmacol. 1998, 6:32-44.
62. Substance Abuse and Mental Health Services Administration, Office of Applied Studies, 2008. Results from the 2007 National Survey on Drug Use and Health: National Findings. NSDUH Series H-34, DHHS Publication No. SMA 08-4343, Rockville, MD.
63. Sañudo-Peña M.C., Romero J., Seale G.E., Fernandez-Ruiz J.J., Walker J.M. Activational role of cannabinoids on movement. Eur. J. Pharmacol. 2000, 391:269-274.
64. Schmitt U., Hiemke C. Tiagabine, a gamma-amino-butyric acid transporter inhibitor impairs spatial learning of rats in the Morris water-maze. Behav. Brain Res. 2002, 133:391-394.
65. Schmitt U., Hiemke C. Effects of GABA-transporter (GAT) inhibitors on rat behaviour in open-field and elevated plus-maze. Behav. Pharmacol. 1999, 10:131-137.
66. Schwartz T.L., Nihalani N. Tiagabine in anxiety disorders. Expert Opin. Pharmacother. 2006, 7:1977-1987.
67. Sofuoglu M., Mouratidis M., Yoo S., Culligan K., Kosten T. Effects of tiagabine in combination with intravenous nicotine in overnight abstinent smokers. Psychopharmacology (Berl) 2005, 181:504-510.
68. Sofuoglu M., Poling J., Mitchell E., Kosten T.R. Tiagabine affects the subjective responses to cocaine in humans. Pharmacol. Biochem. Behav. 2005, 82:569-573.
69. Suzdak P.D., Frederiksen K., Andersen K.E., Sørensen P.O., Knutsen L.J., Nielsen E.B. NNC-711, a novel potent and selective gamma-aminobutyric acid uptake inhibitor: pharmacological characterization. Eur. J. Pharmacol. 1992, 224:189-198.
70. Szabo B., Schlicker E. Effects of cannabinoids on neurotransmission. Handb. Exp. Pharmacol. 2005, 168:327-365.
71. Taylor C.P., Gee N.S., Su T.Z., Kocsis J.D., Welty D.F., Brown J.P., Dooley D.J., Boden P., Singh L.A. A summary of mechanistic hypotheses of gabapentin pharmacology. Epilepsy Res. 1998, 29:233-249.
72. Toland S.L., Green W. DRE field testing of drug impaired drivers. The Effects of Drugs on Human Performance and Behavior: Drugs and Driving/Drugs in the Workplace 1991, American Academy of Forensic Sciences, Colorado Springs, CO. V. Watts (Ed.).
73. Valenzano K.J., Tafesse L., Lee G., Harrison J.E., Boulet J.M., Gottshall S.L., Mark L., Pearson M.S., Miller W., Shan S., Rabadi L., Rotshteyn Y., Chaffer S.M., Turchin P.I., Elsemore D.A., Toth M., Koetzner L., Whiteside G.T. Pharmacological and pharmacokinetic characterization of the cannabinoid receptor 2 agonist, GW405833, utilizing rodent models of acute and chronic pain, anxiety, ataxia and catalepsy. Neuropharmacology 2005, 48:658-672.
74. Vanyukov M.M., Tarter R.E., Kirisci L., Kirillova G.P., Maher B.S., Clark D.B. Liability to substance use disorders 1. Common mechanisms and manifestations. Neurosci. Biobehav. Rev. 2003, 27:507-515.
75. Walsh J.K., Randazzo A.C., Frankowski S., Shannon K., Schweitzer P.K., Roth T. Dose-response effects of tiagabine on the sleep of older adults. Sleep 2005, 28:673-676.
76. Wenger T., Moldrich G. The role of endocannabinoids in the hypothalamic regulation of visceral function. Prostaglandins Leukot. Essent. Fatty Acids 2002, 66:301-307.
77. Westlake T.M., Howlett A.C., Bonner T.I., Matsuda L.A., Herkenham M. Cannabinoid receptor binding and messenger RNA expression in human brain: an in vitro receptor autoradiography and in situ hybridization histochemistry study of normal aged and Alzheimer's brains. Neuroscience 1994, 63:637-652.
78. Wilson W.H., Ellinwood E.H., Mathew R.J., Johnson K. Effects of marijuana on performance of a computerized cognitive-neuromotor test battery. Psychiatry Res. 1994, 51:115-125.
79. Wilson R.I., Nicoll R.A. Endogenous cannabinoids mediate retrograde signaling at hippocampal synapses. Nature 2001, 410:588-592.
80. Zuurman L., Roy C., Schoemaker R.C., Amatsaleh A., Guimaeres L., Pinquier J.L., Cohen A.F., van Gerven G.M.A. Inhibition of THC-induced effects on the central nervous system and heart rate by a novel CB1 receptor antagonist AVE1625. J. Psychopharmacol. 2010, 24:363-371.
81. Zwanzger P., Eser D., Padberg F., Baghai T.C., Schule C., Rötzer F., Ella R., Möller H.J., Rupprecht R. Effects of tiagabine on cholecystokinin-tetrapeptide (CCK-4) induced anxiety in healthy volunteers. Depress. Anxiety 2003, 18:140-143.
82. Zwanzger P., Schule C., Eser D., Baghai T.C., Padberg F., Ella R., Moller H.J., Rupprecht R., Kathmann N. Saccadic eye velocity after selective GABAergic treatment with tiagabine in healthy volunteers. Neuropsychobiology 2005, 52:147-150.